41 – 50 of 131
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia : a meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve
(
- Contribution to journal › Article
-
Mark
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
(
- Contribution to journal › Article
-
Mark
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic : what is the role of stress perception, stress resilience, and β-amyloid?
(
- Contribution to journal › Article
- 2021
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases : An Overview
(
- Contribution to journal › Scientific review